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Abstract: Following environmental pollution exposure, calls to screen the population for disease or
disease markers are often made. Population screening is a cross-sectional review of a population to
find latent cases or biomarkers of disease that indicate the possibility of disease development; it differs
from environmental screening or an epidemiological survey. Recognized standard approaches have
been developed over 60 years to ensure quality and effectiveness in complex programs. We surveyed
the literature for papers on health screening following environmental exposures and checked them for
reference to accepted criteria such as those of Wilson and Jungner. We applied these criteria to three
situations covering source/hazard (arsenic contaminated land), pathway/exposure (radiation release),
and receptor/disease (lead poisoning). We identified 36 relevant papers. Although across the papers
the whole range of criteria were addressed, no paper or program utilized recognized criteria. Issues
and gaps identified included limited strategic approaches, lack of treatment, environmental prevention
being seen as the screening outcome instead of treatment of identified individuals, and programs which
did not fit the World Health Organization screening description. Robust discussion in the literature is
needed to consider the organization and role of health screening following environmental exposures.
Keywords: chemical pollution; mental stress; environmental toxins; potentially harmful elements;
principles of screening; Wilson and Jungner; arsenic; lead; radiation
1. Introduction
Pollution is the largest environmental cause of premature death and disease in the world
today, with a greater impact on global health than cancer. In 2015, it caused an estimated 9 million
premature deaths (16% of all deaths worldwide) and the loss of 268 million disability adjusted
life-years (DALYs—see Box 1) [1]. Air pollution causes 70% of the pollution-related disease burden,
with 1.6–4.8 million premature deaths annually worldwide, predominantly from residential heating and
cooking in Asia [2–4]. The enormous number of contaminated land sites in low- and middle-income
countries from industrial and commercial activities, large and small, put the health of possibly more than
200 million people at risk [2]. There are an estimated 0.5–0.7 million deaths per year from contaminated
soil, heavy metal and chemical exposure combined, with lead on its own contributing another 0.5 million
deaths [1]. Industrial and development-related pollution (including electricity generation, mechanized
agriculture, and petroleum-powered vehicles) has rapidly increased across the globe, with a resulting
continuous increase in pollution and premature deaths [1]. The top 10 contaminating industries
(at all scales) account for 7–17 million DALYs in low- and middle-income countries, with >32 million
people at risk in the industries which span 150,000 sites in about 50 countries [5].
This increase of pollution and resulting ill-health has been ascribed to the current, unsustainable,
economic paradigm which gives little heed to the consequences of recklessly exploiting natural and
human resources [6]. Modelling indicates that premature mortality due to outdoor air pollution could
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double by 2050 [2]. Out of 140,000+ new chemicals since 1950, there are 5000 chemicals which are
most widely dispersed, and which are responsible for adverse human exposures on a global scale.
Environmental exposure of selected chemicals was calculated to cause 8% of all pollution deaths and
6% of the global burden of disease (DALYs) in 2011, which almost certainly underestimates the overall
contribution of chemicals to ill-health and disease [1].
Box 1. Definitions and descriptions.
DALY: Disability adjusted life years—the sum of years of potential life lost due to premature mortality plus
the years of productive life lost due to disability. (World Health Organization. Mental Health. DALYs/YLD
definition. 2020. https://www.who.int/mental_health/management/depression/daly/en/).
PREVENTION: Primary prevention refers to actions aimed at avoiding the manifestation of a disease
(this may include actions to improve health through changing the impact of (environmental) determinants
on health). Secondary prevention deals with early detection when this improves the chances for positive
health outcomes (this comprises activities such as evidence-based screening programs for early detection
of diseases). (World Health Organization. About us. Health promotion and disease prevention through
population-based interventions, including action to address social determinants and health inequity. http:
//www.emro.who.int/about-who/public-health-functions/health-promotion-disease-prevention.html).
SCREENING: The presumptive identification of unrecognized disease in an apparently healthy, asymptomatic
population by means of tests, examinations or other procedures that can be applied rapidly and easily to the
target population. A screening program must include all the core components in the screening process from
inviting the target population to accessing effective treatment for individuals diagnosed with disease. Screening
is a process, beginning with an invitation to participate and ending with treatment for appropriately identified
individuals. Compared to early diagnosis, cancer screening is a distinct and more complex public health
strategy that mandates additional resources, infrastructure and coordination. Screening programs should be
undertaken only when their effectiveness has been demonstrated, when resources are sufficient to cover nearly
all of the target group, when facilities exist for follow-up of those with abnormal results to confirm diagnoses and
ensure treatment and when prevalence of the disease is high enough to justify the effort and costs of screening.
(World Health Organization. Cancer. Screening. 2020. https://www.who.int/cancer/prevention/diagnosis-
screening/screening/en/).
SENSITIVITY and SPECFICITY: Sensitivity is the proportion of people with a disease who have a positive test,
i.e., are correctly diagnosed; specificity is the proportion of people without the disease who have a negative test,
i.e., are correctly eliminated from having the disease. (Cochrane UK. https://uk.cochrane.org/news/sensitivity-
and-specificity-explained-cochrane-uk-trainees-blog).
SYNDROME: A group of symptoms which consistently occur together, or a condition characterized by a set
of associated symptoms.
Children under the age of 15 years bear over half of the overall burden of disease from pollution [7].
Even extremely low-dose exposures to pollutants during windows of vulnerability in utero and in
early infancy can result in disease, disability, and death, both in childhood and later in life [1].
Exposed girls can transmit resulting health disorders to their own children and grandchildren
(e.g., [8,9]). Childhood lead poisoning remains an international public health problem; 97% of children
exposed to toxic levels of lead live in low- and middle-income countries [10], with lifelong adverse
neuropsychological consequences [11,12]. Exposure of children to lead still occurs in high-income
countries, from contaminated land and old paint, amongst other sources [10,11].
The effects of chemical pollution on human health are poorly defined and it is almost certain that
the burden of disease from chemical pollution is underestimated. Fewer than half of the new chemicals
introduced since 1950 have any toxicological testing [1], although a few high-income countries have
recently introduced rigorous pre-market evaluation of new chemicals (for example, [13]). In addition,
the anxiety arising from contamination situations or chemical exposure and the potential for resulting
ill-health consequences can be a major health issue in its own right. Anxiety can often cause more
ill-health than any actual physical disease arising from the exposure, as it may affect more people
than those deemed at risk from the contamination [14,15]. It remains an area that would benefit from
further investigation.
Geosciences 2020, 10, 477 3 of 18
2. Background
Following the identification of an exposure to environmental pollution, it can be appropriate to
consider whether it is possible to identify those people who may be developing disease, in order to give
them early treatment and reduce morbidity and mortality. Population screening (see Box 1) uses an
appropriate test to detect early disease in individuals in a given population; it is cross sectional in time,
although it may be repeated later [16]. Since population health screening finds possible and actual
cases of disease (Figure 1), it differs from surveillance of disease, which is a longitudinal, continuous
review of disease in a population to elucidate the prevalence, incidence, and natural history of the
variables under study. Surveillance operates at a population, not an individual, level. Screening also
differs from impact assessment, whether environmental or health, since these are risk assessments and
not designed to identify individuals with disease. Equally, it differs from the monitoring or screening
of potential pollutants in the environment.
Public health screening of populations has developed from small origins in industry for
occupational diseases in the 1950′s (often due to environmental toxins) to cover a complex range
of diseases, tools, and programs which have been put into place for the general population
(or defined sub-sections) in high-income countries [16–18]. We do not consider occupational health
screening further in this paper. Current examples of population screening programs can be illustrated
by the range of screening in the UK at specific times in life, e.g., pregnancy, at birth, men aged 65, or for
specific diseases, e.g., diabetic eye disease, cervical or breast cancer, and bowel cancer [19].
Early in the burgeoning variety of population health screening programs, a seminal report was
produced in 1968 by two leading experts, Dr James Maxwell Glover Wilson and Dr Gunnar Jungner,
following a commission from the World Health Organization. Wilson was Principal Medical Officer
in the United Kingdom’s Ministry of Health, while Jungner was Chief of the Clinical Chemistry
Department, Sahlgren’s Hospital, Gothenburg, Sweden. Together, Wilson and Jungner reviewed
population health screening and enunciated 10 criteria to be considered when deciding if a population
screening program should be started [17] (Figure 2).
These 10 criteria have stood the test of time [20], being seen as the gold standard when making
decisions about any screening program [21,22]. They stand behind the World Health Organization’s
definition of screening (Box 1). However, they have also been criticized as being too theoretical for
neonatal screening [23], or difficult to assess in a consistent manner [24,25], since they are not wide
enough to capture all the various aspects of modern screening programs [26]. Consequently, several
authors have elaborated on these influential ideas for specific health situations, such as pediatrics [24]
or genetic disorders [25], although most of the changes are around the practical issues of screening,
not the science (Table 1). Many of the newer criteria reflect trends that have reshaped Western medicine
and Western society over the 50 years since the publication of the original criteria, as much as they
reflect advances in science [21]. Some reports have grouped the criteria, the most useful classification
being comprehensive, and easy to remember and apply: (1) the condition to be screened for, (2) the test
to be used, (3) the program to be developed, and (4) the treatment of (or intervention for) positive and
negative cases (Figure 2) [27].
The application to environmental situations remains unclear. There is very little in the literature
on population health screening following a pollution event or environmental exposure, despite a
common question by those responsible for assessing the health impact being, “Can we screen an
exposed population for relevant disease in this pollution situation?”.
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We aimed in this study to identify good practice in the implementation or description of population
health screening related to pollution situations, as determined by the application of recognized criteria
to organize and assess such programs. Our research questions were, what can be learned from a
literature search about the use of a population health screening approach when environmental pollution
is being investigated? Do the approaches used fit with accepted screening criteria? Were any gaps in
knowledge or practice identified?
In order to identify these gaps, we intended to identify relevant criteria and programs and apply
them to three environmental situations that we have met in our public health practice and which reflect
the three aspects of the well-recognized source-pathway-receptor approach to environmental issues.
This environmental approach is parallel to the health perspective of looking at the hazard, the resulting
exposure, and possible ensuing disease or syndrome [28].
Table 1. The changing numbers of population screening criteria 1968–2018, in groups from [17] showing
adaptations to specific situations while validating the original approach.
Date Total Principles Condition Test Program Treatment Source
1968 10 3 2 3 2 Original formulation [17]
1998 19 3 4 9 3 UK general screeningprinciples [27]
2004 20 3 5 8 4 Workshop on geneticimmune-deficiencies [25]
2008 20 3 2 13 2 Synthesis of 50 listscovering 40 years [21]
2018 12 3 2 6 1 Qualitative review toconsolidate 40 lists [20]
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3. Methods
We undertook a literature review in PubMed (https://pubmed.ncbi.nlm.nih.gov/) using major
MESH (Medical Subject Heatings) terms, “Environmental Exposure” or “Environmental Pollution”
and “Mass Screening” or “Diagnostic Screening Programs”. From this initial list, we took an iterative
approach, initially identifying through the title and abstract any papers in English which described
a screening program centered around classical air, land, or water pollution. We read the text of
any relevantly titled paper without an abstract. We excluded papers which were not focused on
the environment and health (e.g., lifestyle issues such as tobacco smoke, alcohol or drugs, exposure
scenarios without specific health outcomes, occupational exposures, and relevant screening of the
environment for hazardous chemical contamination but without relevant health screening). We did
not limit the search to any particular years: The term “mass screening” was added to PubMed in 1968,
“environmental exposure” and “environmental pollution” were introduced in 1974, while diagnostic
screening programs was added in 2019.
Secondly, we searched the full text of the identified papers for any reference to screening criteria,
either the 10 seminal criteria by Wilson and Jungner [17], or another derived set of criteria related
to that original list, or to any pre-selected and objective criteria [26], or the four groups as in [27,29]
(Figure 2). From this, we expected to develop a list of criteria that were considered relevant to
environmental situations.
Thirdly, we assessed the use and understanding of the role of objective criteria in the screening
programs discussed in the scientific literature. Accordingly, we undertook a thematic analysis by
reviewing the papers again and identifying the major themes, whether explicit or implicit, in each
paper according to the identified objective criteria. We initially intended to use the criteria we found in
the literature but where there were none, we resorted to the original 10 criteria of Wilson and Jungner.
We used these classical criteria rather than any others because of their acknowledged utility and
foundational thinking. We considered using other criteria developed from them, as per the background
above (Table 1), but decided that the original 10 criteria were simple and comprehensive enough for an
initial look at environmental pollution. Subsequent criteria were developed for specific health settings
which were not believed to be relevant to this study. Furthermore, we counted the coverage of the four
recognized groups (condition, test, program, and treatment: Figure 2) in each paper.
Once we had completed the literature review, we applied these screening criteria to three
environmental pollution situations which we have encountered, to assess how these criteria supported
making decisions on screening programs relevant to environmental pollution situations and to identify
gaps in knowledge or action that need addressing.
Using the source-pathway-receptor model, which has been beneficially linked to public health
approaches to environmental issues [28,30], we identified areas for further consideration: (1) source/hazard:
Land contaminated by arsenic, (2) pathway/exposure: A radiation release, and (3) receptor/disease:
Lead poisoning in children. We recognized that all three situations need all three components of the
source-pathway-receptor linkage to result in disease. However, we considered this a useful approach
to explore the utility of screening criteria following environmental pollution. This is because the
initial presentation of a contamination situation and its impact on health may be due to the hazard,
the exposure, or the resulting disease (or suspicion).
This was a descriptive study; we did not attempt to undertake any statistical analysis. Such analysis
was unsuited to the questions we were asking and, also, few papers presented any quantitative data
that was comparable with data in other papers.
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4. Results
The literature search on 7th March 2020 identified 242 possible papers from 1962 to 2020. Following
review of the title and abstract we identified 36 papers from 1979 to 2019 on environmentally relevant
population health screening programs.
We reviewed the text of the 36 papers (Table 2) to identify references to objective screening criteria.
No paper used recognized screening criteria to assess the utility of an environmentally-relevant,
population health screening program, whether the original Wilson and Jungner criteria or any others.
Indeed, we were unable to identify any routine public health program of health screening of any
population for environmentally induced disease anywhere that clearly utilized recognized criteria.
We were unable to find any published schema related to screening which we could use to classify
the papers.
Accordingly, our thematic analysis was based on the original Wilson and Jungner criteria (Table 2)
and the four UK screening groups (condition, test, program, treatment) (Figure 2). We found only one
paper, from 2018, which gave adequate information on all 10 criteria in all four groups; only three
other papers (from 1994, 2003, 2008) also covered the four screening groups but with less than full
coverage of the criteria. The fullest paper focused on patient awareness of screening for chronic kidney
disease in Japan, whether of environmental origin or from other causes such as diabetes mellitus or
hypertension, rather than the screening program itself [31] and so was not directly discussing health
screening under objective criteria.
Three other papers, all from the USA, covered the four groups, although missing some of the
10 criteria. One, from 2008, addressed pediatrician’s attitudes and beliefs around environmental
hazards [32]. Another, from 2003, considered the need for a reduction in the blood lead intervention
level [33]. The third paper, from 1994, was a brief strategic look at screening and health risk assessment
related to environmental situations; this paper came the nearest to a full, albeit very short, discussion
of screening as envisaged by the recognized international approach encouraged by the World Health
Organization. The first two of these papers covered only one criterion from each group, while the
third was weak in discussing the health condition to be screened for, perhaps not surprising in a
broad-ranging strategic paper.
As mentioned above, the information on screening criteria was limited in most papers and only
some of the 10 criteria of Wilson and Jungner were covered: 16 (44%) covered one criterion, nine (25%)
two criteria, and five (14%) three criteria. One paper, a 1988 commentary on the then US lead screening
program, did not consider any criteria in any form [34]. Although one paper mentions screening
criteria in the title, these criteria concern choosing children for the study; the paper does not discuss
screening criteria in the sense we used [35]. Fifteen (42%) papers considered the condition, 18 (50%)
the test, 17 (47%) the program and eight (22%) the treatment (Table 2).
Twenty (56%) of the papers were concerned with the health results of lead exposure (13 (36%)
came from the USA). The other papers covered a wide variety of environmental and health situations
(14 topics excluding lead), none with more than two papers.
The USA has had variable success in running population-based health screening for lead poisoning
in children [36–38]. The current verdict on the US program is unclear about how effective screening for
elevated lead levels of asymptomatic children actually is in protecting children from either the health
effects of lead exposure, or from ongoing exposure [38]. Furthermore, the US program, although the
best described and developed program we found, concentrates on prevention. Thus, it does not fit the
WHO definition of a screening program, which is concerned with early identification of disease with
appropriate treatment (Box 1).
Since we could find no examples in the literature of using screening criteria derived for such
situations in assessing actions for environment pollution, we applied Wilson and Jungner’s original
criteria to the three scenarios ((1) land contaminated by arsenic: Source/hazard, (2) a radiation release:
Pathway/exposure, and (3) lead poisoning in children: Receptor/disease). The results are shown in
Table 3. The most important issue we realized was the final criterion, “Is there suitable treatment
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available?”. With no simple treatment options following arsenic contamination, and reduction in
exposure to lead being the main response to elevated blood lead levels, the benefit of implementing
screening programs in these situations remains questionable. This is supported by the literature review
where none of the diseases described are easily amenable to a treatment which will make a substantial
difference to the life of the patient.
Other issues identified included diagnostic methods, timing and tests used, and the lack of a
strategic approach to population health screening in environmental pollution.
The issue of variable results from the diagnostic methods used in the USA lead screening program
was noted in the literature, arising from self-reporting by the potentially exposed community [39] or
questionnaires completed by patients in clinics [40–42]. In another, non-lead, study, the method was
obstetricians questioning of patients: Older obstetricians found it easier to question patients about a
variety of environmental exposures relevant to pregnancy and fetal development than obstetricians
who were more recently qualified. However, the approach appeared somewhat haphazard and did not
seem to have a robust structure [43].
The diagnostic test(s) used for the disease under consideration in a screening program is of vital
importance. Many papers discussed tests (Table 2), but there was little discussion of the sensitivity or
specificity (Box 1) of the tests, an important issue when examining asymptomatic people. Biomarkers
of early disease, before clinical symptoms arise, need to be clearly identifiable. It is worth noting that
specific biomarkers of the relevant disease in the latent phase do not exist at the moment for most
environmentally-induced conditions (Table 3), a point largely ignored in the papers reviewed. Blood
lead level is one of the best recognized biomarkers for exposure (not necessarily of disease), whether
current or in the past, and was the most discussed (11 papers).
Monitoring of radiation levels of exposed people is carried out too early to identify latent disease.
Rather, it identifies exposure to radiation and its main benefit is to assure the worried well that they
have not been exposed to significant radiation from the incident. Anyone with significant exposure can
be followed up through a register [44,45]. However, this is monitoring, not screening. Post-radiation
monitoring is another example of a program that some might considered to be screening but does not
fit the definition.
The lack of a strategic approach to screening programs was seen in the limited number of papers
on any subject other than lead poisoning and in narrow the focus on subsections of the four groups or
10 criteria (Table 2).
Further to these three important points (lack of treatment, diagnostic issues, and strategic
approaches) specific gaps in knowledge relevant to screening programs can be further identified
through the worked examples in Table 3. However, any such gaps are secondary to the lack of a
systematic and strategic approach to screening and the lack of suitable treatments, which render
programs ineffective and make any other knowledge and practice gaps of lesser, even limited,
importance. Accordingly, we did not pursue these further at this time.
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Table 2. Coverage in the literature review papers, within four recognized screening groups, of the 10 Wilson and Jungner screening criteria [17], showing the number
of criteria covered and the group into which they fall.
Year Focus of Paper Condition Test Program Treatment Number of Criteria Groups Total Criteria Quoted Source
2019 Review of Pb program. USA 1 1 2 2 [38]
2018 Obstetrics screening for environmental exposure. USA 3 1 3 [43]
2018 CKD screening. International 3 2 3 2 4 10 [31]
2017 COPD. Japan 1 1 1 [46]
2017 Legal; harm/benefit. USA 3 1 2 4 [47]
2015 Pre-pregnancy CH3Hg. Canada 1 1 1 [48]
2015 Predicting BLL >50. France 1 1 1 [35]
2012 Predicting BLL. NV, USA 1 1 1 [42]
2012 Predicting BLL and costs. MI, USA 1 2 2 3 [39]
2011 Rapid radiation test. NYC, USA 1 1 1 [49]
2009 Determining Pb exposed population. GA, USA 1 1 1 [50]
2009 Bladder Cancer. USA 2 1 2 [51]
2008 Radiation risk communications. TX, USA 1 1 1 [52]
2008 Pediatricians’ attitudes & beliefs. MN, USA 1 1 1 1 4 4 [32]
2008 Not attending for BLL, NSW, Australia 1 1 2 2 [53]
2007 Biomonitoring concentrations. USA 1 1 1 [54]
2007 Predicting BLL >100. France 1 1 1 [55]
2007 Health outcomes of war. Iran 1 1 1 [56]
2004 Indian children’s lead. USA 1 1 1 [57]
2004 Pb epidemiology in children. Chicago, USA 1 1 2 2 [58]
2003 BLL levels. USA 1 1 1 1 4 4 [33]
2002 Scoliosis screening. Greece 2 1 2 [59]
2001 Dioxin. Japan 1 1 1 [60]
2001 Screening age >36 m ineffective; Pb. NY, USA 2 1 2 3 [61]
1999 Pb costs. MN, USA 1 1 2 2 [62]
1999 Screening women for Pb. NY, USA 2 1 2 [63]
1998 Comment on CDC Pb guidelines. USA 0 0 [34]
1997 Ease of blood testing, Pb. NY, USA 1 1 1 [64]
1996 Telephone review Pb screening. USA 1 1 2 2 [65]
1994 Screening tool, Pb. WI, USA 1 1 1 [40]
1994 Predicting BLL. CA, USA 1 1 2 2 [41]
1994 Strategies for health screening. USA 1 2 2 2 4 7 [66]
1993 Pediatric BLL pilot. AK, USA 1 1 1 [67]
1992 GIS for Pb screening. USA 1 1 1 [68]
1984 Dioxin pilot. MO, USA 2 1 2 3 [69]
1979 Testing for Cd. Japan 2 1 2 3 [70]
Notes: BLL = blood lead level; CDC = Centre for Disease Control; CKD = chronic kidney disease; COPD = chronic obstructive pulmonary disease; GIS = Geographical Information System.
Other abbreviations are elements or states.
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Table 3. Using population screening following environmental contamination: Three worked examples assessed against Wilson and Jungner [17] criteria.
Criterion [17] Soil Arsenic Radiation Exposure Childhood Lead
Condition
Natural history of condition adequately
understood Not adequately Well understood Yes, clear links between BLL and disease
Important health problem Cancers and disfiguring skin problemscan result Politically, socially, medically important Lifelong neuropsychological effects
Recognizable latent/early stage
No single identifiable early condition;
markers sensitive but not specific for
environmental source
Main thrust of program is to reassure the
“worried well”. Latent stage of disease
comes much later than the “screening”
Unclear if low BLL indicates future high
BLL or just low exposure
Test
Suitable test or examination Sensitive, but not specific as to sourceof As
Yes, but detects contamination by
radiation, not disease BLL
Acceptable to population Blood, urine, hair sampling arevariously acceptable Yes
Blood test; not always acceptable
to children
Program
Ongoing case-finding process Needs commitment and resources Resource intensive initially Needs organizing centrally.Needs commitment and resources
Case costs economically balanced with
expenditure on medical care Unknown
No, but high level of reassurance
can be given Yes
Diagnostic & treatment facilities
available No Yes, for contamination Yes
Treatment
Accepted treatment No Depends on resulting disease Limited to high BLL
Agreed policy on whom to treat No Well worked out for contamination No; focus is on prevention not treatment
BLL = blood lead level.
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5. Discussion
We searched the scientific literature for appropriate ways to undertake population health screening
in environmental pollution situations, using accepted screening criteria. To our knowledge, this is the
first time that such approaches have been reviewed in the literature. We found no environmentally
related programs which overtly discussed the 10 seminal criteria from Wilson and Jungner’s report [17]
or other accepted criteria.
We found important gaps: Firstly, there is a current lack of treatment for any resulting disease
in three representative scenarios covering source (hazard), pathway (exposure), and receptors
(syndrome or disease). This is in line with the fact that few (8; 22%) of the papers we found
covered treatment. This was less than half of the number of papers discussing the test (18; 50%) or
the program (17; 47%) and much less than the papers discussing the condition (15; 42%). This raises
questions about the utility of current screening approaches to the detection of disease arising from
environmental pollution. What is the point of screening if there is no answer for the patient for their
identified health issues? However, recent advances in early diagnosis and simpler treatments suggest
that this lack of current treatments is not a fatal flaw for pollution-related health screening programs;
it is possible that relevant tests and treatments will be developed that enable such screening programs
to be developed for diseases related to environmental exposures.
The need for good biomarkers of disease is crucial. Finding suitable biomarkers to identify early
disease resulting from arsenic contamination can be problematical [71,72]. Few biomarkers are as
well understood as blood lead level, a clear marker for lead exposure having occurred at some point,
whether current or in the past. The concentration of blood lead can be a pointer to the particular disease
expected (low lead levels affect neurocognitive development; higher concentrations give anemia or
gastrointestinal problems), but there is no treatment at the lower concentrations, only removal of
source. At higher concentrations (>45 µg/dL), chelation therapy may be used, but the aim of this
treatment is to reduce the high blood lead level; it does not directly address the resulting disorders.
Secondly, and perhaps more importantly, we found limited discussion around how to
systematically organize and evaluate such screening programs, although the variety of issues covered
is encouraging. The lack of reference to, or engagement with, the extensive health screening literature
was disappointing, showing an important lack of appreciation of the need for a strategic approach
to program planning. Since the publication of the seminal criteria [17] there has been ongoing
debate and refinement of the approaches to the organization of health screening, with aspects such as
quality control, economics, and outcomes being monitored and improved. Furthermore, the extensive
enlargement across a variety of health fields of the Wilson and Jungner criteria (as illustrated in Table 1)
to produce relevant criteria that can be used objectively to structure and evaluate programs has no
parallel in the environment—health interface, leaving plenty of room for development.
Only four papers covered all four of the screening groups (condition, test, program, and treatment),
suggesting that few authors, although writing about their own screening situation, were aware of the
abundant screening literature. Such a situation might be due to the compartmentalization of science
with increasing knowledge on the one hand, and the pressure on outcome measures in programs on
the other, although there may be other as yet unrecognized reasons.
Given that population health screening has a long and successful history, and pollution is an
important and worldwide cause of morbidity and mortality, these gaps are disappointing. Population
screening programs are recognized to need a structured approach to ensure that the program is wide
and informed (Box 1) [21,22,73,74]. The scrutiny of the US lead screening program, raising questions
about the efficacy of screening asymptomatic children [38], is an example of much needed discussion.
The succinct paper by Wallace and Murray [66] covers much of the ground for discussion without
focusing on any specific disease outcome from environmental pollution. That paper appears to be as
unknown as the more general screening literature but should be recommended reading for anyone
considering health screening related to pollution.
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The Wallace and Murray paper from 1994 focused on prevention in contradistinction to the focus
of extant health screening programs on early diagnosis and treatment. These programs often focus on
a single disease, e.g., breast cancer or aortic aneurysm. The issue in many of the screening programs
is that, while the natural history (progression) of the disease is understood, the etiology is unknown.
Treatment, then, becomes all that can be offered, and the earlier the better. However, in environmental
pollution, the exposure is known or suspected, even if knowledge about any latent period of the
disease, during which early diagnosis becomes possible, is unclear. As a result, the focus of response
in environmental situations should be different from the more medical situations. For example, lead
screening programs in children aim to identify exposed children and respond to the exposure, as well as
to the child with raised blood lead levels.
This raises the question: Is the current WHO definition of health screening (Box 1) too narrow
and medically focused? Should it include prevention as well as treatment as the outcome? Or, if not
prevention, then, as in lead, a recognition of exposure and the consequent removal of the source or the
pathway, which is helpful if not curative. Discussion around the role of screening in environmental
pollution situations could help widen thinking about screening in the health community.
Such a shift in thinking about screening outcomes needs a corresponding move concerning the
underlying approach to health issues. The medical model of health concentrates on diagnosis and
treatment of disease and still plays a major role in the design and delivery of health services and
the understanding of health in many communities. It has been criticized for its limited approach,
ignoring social, economic, and environmental factors in the causation and control of ill-health [75].
Public health has moved to a bewildering array of 21 or more different versions [76] of a wider
socio-economic [77]/socio-ecological [78]/socio-environmental [79] model. These models take into
account a broader range of the issues determining health. Nevertheless, the role of the environment,
whether natural or man-made, is often underestimated or even overlooked, with the focus primarily
on lifestyle choices. Environmental pollution is not a choice; issues of pollution are pervasive
while the resulting exposures are only slowly being quantified and acknowledged [79] by the wider
community [1,2,4,5,80].
Pollution often arises from a mixture of chemicals, giving multiple and interacting exposures,
from which a variety of diseases may result. While this is recognized within the environmental
science community, the effect of chemical mixtures remain less explored on the health side [81,82].
Similarly, there can be either acute or chronic exposures to a pollutant, which may give rise to
different health outcomes. Screening for some health condition needs to be repeated on a regular
basis, (e.g., breast cancer screening), since there is the possibility of developing disease after the initial
screening. This may be equally important in pollution situations. All these issues are further reasons
to generate discussion across the environmental-health border, involving both communities.
The US lead screening program highlights the need for prevention [38]. Perhaps the definition of
a screening program should be expanded to include prevention rather than a sole focus on treatment
as the outcome of the program. However, screening for prevention is more complex than screening
for early disease detection. Screening for prevention needs to include screening of the environment
for hazardous chemical contamination, as well as population health screening to find early, treatable
disease arising from such exposure. Risk assessment and risk management of the source (hazard)
and pathway (exposure) to reduce possible exposure is as important as health screening for resulting
disease (receptor). Further, health screening should never replace primary prevention (Figure 1) (Box 1).
Health screening is, at best, a form of secondary prevention (Box 1). While prevention can bring about
greater health benefits than the early identification of disease, both can be beneficial but contribute in
different ways.
Of course, science is not everything, even in screening. Policy often trumps science and there may
be ethical decisions beyond the relevance of screening criteria that need to be taken into account [83,84].
Values will always be more influential than evidence in deciding policy [85]. Nevertheless, this does
not justify not using the science when it is available.
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The strengths of this study include being the first to apply widely recognized criteria on
screening to pollution-related health situations. We used multiple methods (triangulation) to develop
a comprehensive understanding and increase the reliability of our findings. The literature was
examined for mention or discussion of objective screening criteria in the design or operation of the
program, a thematic analysis of papers against recognized screening criteria was undertaken, and we
applied recognized criteria to the three case studies covering the source-pathway-receptor approach
to pollution. These differing approaches consistently revealed basic weaknesses in environmentally
related population health screening approaches, increasing the dependability of the conclusions.
Weaknesses of the study include the limited literature review of screening programs, due to the
constraints of resources and the Covid-19 situation. Grey literature was not searched; it is possible that
there are screening programs adhering to standard approaches, but which have not been recorded in
the academic literature. The subject needs a wider and more detailed literature review than we were
able to undertake.
6. Conclusions
We recommend that health screening programs related to environmental pollution need to be
more systematically developed to ensure that they achieve their intended outcomes. They should
be guided by appropriate criteria, which may need to be further developed for pollution situations.
They need to be consistent with wider health policy issues. They should not expect clinicians to ask
relevant questions without careful planning and evaluation of the whole program [32,43].
We therefore recommend that a vigorous discussion is undertaken across the public health and
environmental communities about the use of screening in the management of pollution events. This has
been done for other health issues arising from specific determinants (e.g., genetic diseases [25,86]) or in
specific situations (e.g., pediatric/neonatal screening [24]). Such a discussion needs to happen before
any further identification of knowledge gaps; indeed, such a discussion would help identify the gaps
in more detail. The identification of gaps would also clarify areas for further research, whether source,
pathway or receptor, condition, test, program or treatment [66].
This discussion should include an assessment of whether or not, or when, such programs are
needed, the criteria for organizing and evaluating the programs, the information needed to run a
useful program, the strength of evidence on which to base a program (including evidence of sensitivity
and positivity of the tests and efficacy of the treatment), agreed outcomes, whether treatment or
preventative activities, and defined strategies for dealing with people with positive or negative tests.
Since the potential number of environmental scenarios is large, it would be a mistake to attempt
to develop a stand-alone program for each chemical or disease. Rather, a strategic approach should
take into account different sources/hazards, pathways/exposures, and receptors/diseases or syndromes
to help guide further relevant and useful programs. However, any generic approach should be flexible
enough to be adapted in specific situations. Wilson and Jungner wrote, “In theory, screening is an
admirable method of combating disease . . . in practice, there are snags”, and “[screening] is far from
simple though sometimes it may appear deceptively easy” [17]. This is still true.
Sir Muir Gray, former director of the UK National Screening Committee, wrote with colleagues,
“All screening programmes do harm; some do good as well, and, of these, some do more good than
harm at reasonable cost. The first task of any public health service is to identify beneficial programmes
by appraising the evidence. However, evidence of a favourable balance of benefit to harm in a
research setting does not guarantee that a similar balance will be reproduced in practice, so screening
programmes need to be introduced in a way that allows their quality to be measured and continuously
improved.” [74].
An evaluation of the usefulness of implementing a population health screening program
after environmental exposure to pollutants is urgently needed, through a wider discussion in the
wider public health community, including toxicologists, epidemiologists, clinicians, policy makers,
and environmental scientists. Toxicologists and clinicians understand patients and their diseases,
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but environmental scientists understand the source-pathway-receptor approach to environmental
situations that parallels the hazard-exposure-disease pathway that health professionals are used to.
The standard approaches to developing and running a screening program need to be evaluated in the
light of pollution exposures. If such an approach is beneficial it would reduce the ill-health from an
exposure. If it is not, it can then be discarded, saving time and resources.
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